Taken together, fusion-typing of a novel panel of TMPRSS2:ETS fusion markers allows detection of diverse fusion types in urine; multiple alternative fusion markers other than the common subtype I provide improved detection of prostate cancer in prebiopsy patients. The gene discussed is TMPRSS2; the disease is prostate carcinoma.